1395493-30-7

Basic information

• Product Name: Methyl 2-aMino-4-broMo-5-fluorobenzoate
• Synonyms: Methyl 2-aMino-4-broMo-5-fluorobenzoate
• CAS NO: 1395493-30-7
• Molecular Formula: C8H7BrFNO2
• Molecular Weight: 248.0490832
• EINECS: -0
• Mol File: 1395493-30-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 331.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.653±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.22±0.10(Predicted)
• CAS DataBase Reference: Methyl 2-aMino-4-broMo-5-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-aMino-4-broMo-5-fluorobenzoate(1395493-30-7)
• EPA Substance Registry System: Methyl 2-aMino-4-broMo-5-fluorobenzoate(1395493-30-7)

Safety Data

• Hazardous Substances Data: 1395493-30-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-amino-4-bromo-5-fluorobenzoate is a compound belonging to the class of benzoic acid esters. It is a derivative of benzoic acid with a methyl group, an amino group, a bromine atom, and a fluorine atom attached to the benzene ring. Methyl 2-aMino-4-broMo-5-fluorobenzoate is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various pharmaceuticals and agrochemicals. Due to the presence of an amino group and a fluorine atom, it may have potential biological activities and could serve as a valuable intermediate in the development of new pharmaceutical compounds. However, it is important to handle this compound with care as it may be harmful if ingested, inhaled, or comes into contact with the skin.

Upstream product

• 849758-12-9 methyl 4-bromo-3-fluorobenzoate 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 1220886-29-2 methyl 4-bromo-5-fluoro-2-nitrobenzoate 
• 1020717-99-0 4-bromo-5-fluoro-2-nitrobenzoic acid 

Relevant articles and documents

Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2

Detailed structure activity relationship of two series of quinazoline EHMT1/EHMT2 inhibitors (UNC0224 and UNC0638) have been elaborated. New and active alternatives are presented for the ubiquitous substitution patterns found in literature for the linker to the lysine mimicking region and the lysine mimic itself. These findings could allow for advancing EHMT1/EHMT2 inhibitors of that type beyond tool compounds by fine-tuning physicochemical properties making these inhibitors more drug-like.

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria

Since their discovery over 5 decades ago, quinolone antibiotics have found enormous success as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase and topoisomerase IV. Increasing rates of resistance, driven lar

CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS

The present invention provides a compound having the structure:, or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorder, borderline personality disorder, opioid addiction, or opioid withdrawal symptoms by administering the compound to the subject.